The Launch of Boehringer Ingelheim’s One Medicine Program

episode

Unblinded: A Clinical Trial Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

#502 – Psychiatry, Insane Asylums, Mental Illness, ECT, Lobotomies, Freud & Jung 3h 43m · 17 Sep 2026 · Lex Fridman Podcast

Your partner wants profit. You want freedom. Now what? 22 min · 16 Sep 2026 · The Optometry Success Podcast

Board of County Supervisors Meeting - Work Session - Sep 15, 2026 3h 17m · 15 Sep 2026 · Prince William County Board of Supervisors

Finance and Budget Committee - Sep 15, 2026 1h 43m · 15 Sep 2026 · Prince William County Finance and Budget Committee

Sept. 15, 2026 Board of Supervisors Meeting 8h 46m · 15 Sep 2026 · Fairfax County Board of Supervisors

The Art of True Happiness | Dr. Arthur Brooks 2h 49m · 14 Sep 2026 · Huberman Lab

Report any issue

Source

Recorded04 Oct 2024

Publisherfeed.podbean.com ↗

Handlerec:14731157

Show notes

Nicole Raleigh hosts this special episode on-site from Boehringer Ingelheim’s Human Pharmacology Center in Biberach, Germany. Andrea Kloeble and Daniel Schwenk are part of the team reimagining drug development at Boehringer Ingelheim through the One Medicine Platform. They explain how their organization strives for medical excellence, and why exponential growth in study data volumes and sources requires a connected technology ecosystem. And Richard is in the guest seat this week to put this transformative initiative into industry context: as he explains, life sciences is no longer willing to accept single-use data.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in